Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tempus AI, Inc. Class A (TEM)
NASDAQ:TEM
RESEARCH TOOLSreports
Holding TEM?
Track your performance easily
TEM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$22.89 - $77.00
Previous Close$49.38
Volume1.36M
Average Volume (3M)1.22M
Market Cap
$8.44B
Enterprise Value$8.01B
Total Cash (Recent Filing)$94.90M
Total Debt (Recent Filing)$485.20M
Price to Earnings (P/E)―
Beta3.04
Next Earnings
Aug 06, 2024EPS Estimate
-$3.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding154,318,712
10 Day Avg. Volume1,162,154
30 Day Avg. Volume1,221,355
Standard Deviation0.10
R-Squared1.00
Alpha0.10
Financial Highlights & Ratios
Price to Book (P/B)-5.72
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue54.93
Enterprise Value/Gross Profit27.99
Enterprise Value/Ebitda-197.20
Forecast
1Y Price Target
$46.00Price Target Upside-15.86% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Tempus AI, Inc. Class A News
Bulls Say, Bears Say
Bulls Say
Market PotentialTempus serves a large total addressable market (TAM) of at least $70bn, and has achieved impressive scale in a short period of time.
Partnerships And ContractsTempus has the ability to sign large partnerships, win large health care systems and receive high reimbursement in a number of testing areas.
Revenue GrowthTempus also sells data, software, and AI, generating over $200M in data revenue in 2024, growing at around 35%.
Bears Say
Financial PerformanceTempus is burning through cash, and its ability to achieve profitability and turn cash-flow-positive is uncertain.
Regulatory And Legal RisksThere are significant regulatory and legal risks in terms of reimbursement for its Dx menu, for the novel and unproven ‘AI Algorithms’ business, and for patient healthcare data privacy.
RevenueThe company needs to generate more revenue in its AI business before getting a top industry multiple.
---
Ownership Overview
52.57% Insiders
0.88% Mutual Funds
18.11% Other Institutional Investors
28.44% Public Companies and Individual Investors
TEM FAQ
What was Tempus AI, Inc. Class A’s price range in the past 12 months?
Tempus AI, Inc. Class A lowest stock price was $22.89 and its highest was $77.00 in the past 12 months.
What is Tempus AI, Inc. Class A’s market cap?
Currently, no data Available
When is Tempus AI, Inc. Class A’s upcoming earnings report date?
Tempus AI, Inc. Class A’s upcoming earnings report date is Aug 06, 2024 which is 44 days ago.
How were Tempus AI, Inc. Class A’s earnings last quarter?
Currently, no data Available
Is Tempus AI, Inc. Class A overvalued?
According to Wall Street analysts Tempus AI, Inc. Class A’s price is currently Overvalued.
Does Tempus AI, Inc. Class A pay dividends?
Tempus AI, Inc. Class A does not currently pay dividends.
What is Tempus AI, Inc. Class A’s EPS estimate?
Tempus AI, Inc. Class A’s EPS estimate is -$3.55.
How many shares outstanding does Tempus AI, Inc. Class A have?
Tempus AI, Inc. Class A has 149,274,920 shares outstanding.
What happened to Tempus AI, Inc. Class A’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tempus AI, Inc. Class A?
Among the largest hedge funds holding Tempus AI, Inc. Class A’s share is ARK Investment Management LLC. It holds Tempus AI, Inc. Class A’s shares valued at 18M.
---
Tempus AI, Inc. Class A Stock Smart Score
Company Description
Tempus AI, Inc. Class A
Tempus AI endeavors to unlock the true power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence in healthcare. Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal. To accomplish this, we built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Our proprietary technology has allowed us to amass what we consider to be one of the largest libraries of clinical and molecular oncology data in the world. We have launched a suite of different products derived from our Platform, which have gained significant traction over the past five years. To date, our offerings have been used by approximately 95% of the largest public pharmaceutical companies.
---
TEM Company Deck
---
TEM Earnings Call
Q2 2024
0:00 / 0:00
---
TEM Stock 12 Month Forecast
Average Price Target
$46.00
▼(-15.86% Downside)
Technical Analysis
Best Analysts Covering TEM
1 Year
1 Year Success Rate
2/2 ratings generated profit
1 Year Average Return
+36.10%
reiterated a buy rating 2 months ago
Copying Daniel Arias's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +36.10% per trade.
---